<DOC>
	<DOCNO>NCT00661531</DOCNO>
	<brief_summary>This trial seek confirm response rate estrace treatment patient hormone receptor positive metastatic breast cancer heavily pre-treated modern endocrine therapy .</brief_summary>
	<brief_title>Estrogen Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure Sequential Endocrine Therapy</brief_title>
	<detailed_description>Prior current standard care utilize estrogen deprivation antiestrogen therapy treat hormonally sensitive breast cancer , treatment pharmacologic dose estrogen common technique use treat post-menopausal woman hormone sensitive metastatic disease result durable response regression disease . A randomized trial compare tamoxifen pharmacologic dos estrogen demonstrate similar rate response long-term follow-up data confirm survival benefit treat estrogen preparation . Additional data show post-menopausal woman hormonally sensitive tumor progress prior endocrine therapy respond treatment pharmacologic dose estrogen . These data , couple pre-clinical data postmenopausal level estrogen use cause apoptosis ( program cell death within tumor ) tumor regression exhaustively treat endocrine resistant disease form rationale propose clinical trial . This trial seek confirm response rate estrace treatment patient population heavily pre-treated modern endocrine therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Histologically confirm estrogen and/or progesterone receptorpositive breast cancer metastatic breast cancer Clinically determine evaluable disease Postmenopausal woman Previous clinical benefit prior antiestrogen therapy subsequent failure least 2 prior endocrine therapy . May chemotherapy adjuvant &amp; /or metastatic disease . May radiation therapy site disease . Ecog performance status &lt; /= 2 . Life expectancy &gt; 6 month Chemotherapy radiotherapy within 1 week begin treatment clinical trial Brain metastasis Prior history active thrombophlebitis , deep venous thrombosis pulmonary embolus Current vaginal bleeding Hypercalcemia hypocalcemia History active hepatic adenoma No malignancy within past 5 year exception curatively treat basal cell squamous cell carcinoma skin carcinoma insitu cervix</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>ER positive breast cancer</keyword>
	<keyword>Hormonal therapy</keyword>
</DOC>